신라젠

215600KOSDAQ자연과학 및 공학 연구개발업

58.3 / 100

Reference Date: 2026-04-13

Financial Score21.0 / 40

News Sentiment16.3 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Rose 10.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Shinara Gen is a biotech venture company established in 2006, focusing on developing anti-cancer drugs. The company specializes in oncolytic virus therapies, mitotic checkpoint inhibitors, and generic pharmaceuticals. Its oncolytic viruses selectively target cancer cells and are being studied in combination therapies with immune checkpoint inhibitors.

Number of Employees

56people

Average Salary

82.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

4.71Industry Average 3.822.5Point

Higher than industry avg (caution)

ROE

-20.00Industry Average -32.113.5Point

Below industry avg

Debt Ratio

1.50Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲67.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼10.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -26.0% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 3Neutral 0Negative 0Average Sentiment Score 80

Positive
신라젠, 7조 AML 항암제 시장 정조준… '전략·연구통' 전면에
신라젠은 정기주주총회에서 각자대표 체제로 경영진을 재편하고 연구개발(R&D) 투자 강화와 경영 효율성에 집중하며, 우성제약 인수를 통해 외형 성장을 본격화하고 있습니다.
Positive
신라젠, 한상규·박상근 각자대표 체제 출범
신라젠은 한상규 부사장과 박상근 전무를 신임 각자대표이사로 선임하며 전략과 연구개발 역량을 강화했습니다.
Positive
신라젠, 정맥투여 항암바이러스 ‘SJ-650’ 기전 규명…전신 치료 가...
신라젠은 이동섭 서울대 의대 교수팀과 공동 연구한 차세대 항암백신 후보물질 'SJ-650'이 정맥투여를 통해 전신 암세포를 공격할 수 있는 원리를 밝혀내 국제학술지에 게재했습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (56%)

Current 3,755Won52-week high 4,97552-week low 2,165

1-month return5.0Point

1m +9.96% (rising)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral대표이사변경2026-03-27
Neutral정기주주총회결과2026-03-27
Neutral사업보고서 (2025.12)2026-03-19
Neutral감사보고서제출2026-03-19